OrthO-rheumatO | VOL 12 | Nr 2 | 2014
18
24. ruggiero s, gralow j, marx re, et al. Practical guidelines for the prevention, diagnosis,
and treatment of osteonecrosis of the jaw in patients with cancer. j oncol Pract
20062(1):7-14.
25. shane e, Burr d, abrahamsen B, et al. atypical subtrochanteric and diaphyseal femoral
fractures: second report of a task force of the american society for Bone and mineral
research. j Bone miner res 2014;29(1):1-23.
26. Bell jk, hayen a, irwig l, et al. The potential value of monitoring bone turnover markers
among women on alendronate. j Bone miner res 2012;27(1):195-201.
27. mcClung m. Controversies in osteoporosis management: concerns about
bisphosphonates and when are "drug holidays" required? Clin obstet gynecol
2013;56(4):743-8.
28. Baron r, ferrari s, russell rg. denosumab and bisphosphonates: different mechanisms
of action and effects. Bone 2011;48(4):677-92.
29. kostenuik Pj, nguyen hQ, mcCabe j, et al. denosumab, a fully human monoclonal
antibody to rankl, inhibits bone resorption and increases Bmd in knock-in mice that
express chimeric (murine/human) rankl. j Bone miner res 2009;24(2):182-95.
30. Cummings sr, san martin j, mcClung mr, et al. denosumab for prevention of fractures in
postmenopausal women with osteoporosis. n engl j med 2009;361(8):756-65.
31. Papapoulos s, lippuner k, roux C, et al. eight years of denosumab treatment in
postmenopausal women with osteoporosis. results from the first five years of the
freedom extension. abstract lB-mo26. Presented at the american society of Bone and
mineral research 2013 annual meeting; oct. 4-7, 2013; Baltimore.
32. stopeck aT, lipton a, Body jj, et al. denosumab compared with zoledronic acid for the
treatment of bone metastases in patients with advanced breast cancer: a randomized,
double-blind study. j Clin oncol 2010;28(35):5132-9.
33. fizazi k, Carducci m, smith m, et al. denosumab versus zoledronic acid for treatment
of bone metastases in men with castration-resistant prostate cancer: a randomised,
double-blind study. lancet 2011;377(9768):813-22.
34. henry dh, Costa l, goldwasser f, et al. randomized, double-blind study of denosumab
versus zoledronic acid in the treatment of bone metastases in patients with advanced
cancer (excluding breast and prostate cancer) or multiple myeloma. j Clin oncol
2011;29(9):1125-32.
35. stolina m, dwyer d, ominsky ms, et al. Continuous rankl inhibition in osteoprotegerin
transgenic mice and rats suppresses bone resorption without impairing
lymphorganogenesis or functional immune responses. j immunol 2007;179(11):7497-
505.
36. Bekker Pj, holloway dl, rasmussen as, et al. a single-dose placebo-controlled study of
amg 162, a fully human monoclonal antibody to rankl, in postmenopausal women. j
Bone miner res 2004;19(7):1059-66.
37. watts nB, roux C, modlin jf, et al. infections in postmenopausal women with
osteoporosis treated with denosumab or placebo: coincidence or causal association?
osteoporos int 2012;23(1):327-37.
38. Papapoulos s, Chaputlat r, libanati C, et al. five years of denosumab exposure in women
with postmenopausal osteoporosis: results from the first two years of the freedom
extension. j Bone miner res 2012;27(3):694-701.
39. lipton a, fizazi k, stopeck aT, et al. superiority of denosumab to zoledronic acid for
prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised,
phase 3 trials. eur j Cancer 2012;48(16):3082-92.
40. Body jj, Bergmann P, Boonen s, et al. management of cancer treatment-induced bone
loss in early breast and prostate cancer a consensus paper of the Belgian Bone Club.
osteopor int 2007;18(11):1439-50.
41. gronich n, rennert g. Beyond aspirin-cancer prevention with statins, metformin and
bisphosphonates. nat rev Clin oncol 2013;10(11):625-42.
42. mhaskar r, redzepovic j, wheatley k, et al. Bisphosphonates in multiple myeloma: a
network meta-analysis. Cochrane database syst rev 2012 may 16;5:Cd003188.
43. Ben-aharon i, Vidal l, rizel s, et al. Bisphosphonates in the adjuvant setting of breast
cancer therapy--effect on survival: a systematic review and meta-analysis. Plos one
2013.8(8)e70044.
44. Valachis a, Polyzos nP, Coleman re, et al. ajduvant therapy with zoledronic acid
in patients with breast cancer: a systematic review and meta-analysis. oncologist
2013;18(4):353-61.
45. wong mh, stockler mr, Pavlakis n. Bisphosphonates and other bone agents for breast
cancer. Cochrane database syst rev 2012 feb 15;2:Cd003474.
46. rennert g, Pinchev m, rennert hs. use of bisphosphonates and risk of postmenopausal
breast cancer. j Clin oncol 2010;28(22):3577-81.
47. Chlebowski rT, Chen Z, Cauley ja, et al. oral bisphosphonate use and breast cancer
incidence in postmenopausal women. j Clin oncol 2010;28(22):3582-90.
48. lopez-olivo ma, shah na, Pratt g, et al. Bisphosphonates in the treatment of patients
with lung cancer and metastatic bone disease: a systematic review and meta-analysis.
support Care Cancer 2012;20(11):2985-98.
49. rennert g, Pinchev m, rennert hs, gruber sB. use of bisphosphonates and reduced risk
of colorectal cancer. j Clin oncol 2011;29(9):1146-50.
50. Pazianas m, abrahamsen B, eiken Pa, et al. reduced colon cancer incidence and
mortality in postmenopausal women treated with an oral bisphosphonate--danish
national register based cohort study. osteoporos int 2012;23(11):2693-701.
51. singh h, nugent Z, demers a, mahmud s, Bernstein C. exposure to bisphosphonates
and risk of colorectal cancer: a population-based nested case-control study. Cancer
2012;118(5):1236-43.
52. khalili h, huang es, ogino s, fuchs Cs, Chan aT. a prospective study of bisphosphonate
use and risk of colorectal cancer. j Clin oncol 2012;30(26):3229-33.
53. Passarelli mn, newcomb Pa, laCroix aZ, et al. oral bisphosphonate use and colorectal
cancer incidence in the women's health initiative. j Bone miner res 2013;28(9):2043-8.
54. mason md, sydes mr, glaholm j, et al. oral sodium clodronate for nonmetastatic
prostate cancer--results of a randomized double-blind placebo-controlled trial: medical
research Council Pr04 (isrCTn61384873). j natl Cancer inst 2007;99(10):765-76.
55. green j, Czanner g, reeves g, watson j, wise l, Beral V. oral bisphosphonates and risk
of cancer of oesophagus, stomach, and colorectum: case-control analysis within a uk
primary care cohort. Bmj 2010;341 doi: http://dx.doi.org/10.1136/bmj.c4444
56. Cardwell Cr, abnet CC, Cantwell mm, murray lj. exposure to oral bisphosphonates and
risk of esophageal cancer. jama 2010;304(6):657-63.
Ortho-Rheumato ook op internet
www.ortho-rheumato.be
NY/S
T/1
4/0006